When was MiNA Therapeutics founded?

MiNA Therapeutics was founded in 2008 and raised its 1st funding round 6 years after it was founded.

Where is MiNA Therapeutics located?

MiNA Therapeutics is headquartered in London, United Kingdom. It is registered at Translation & Innovation Hub 80 Wood Lane London W12 0BZ United Kingdom.

Who is the current CEO of MiNA Therapeutics?

Robert Sebastian Habib of MiNA Therapeutics.

Which legal entities is MiNA Therapeutics associated with?

MiNA Therapeutics is associated with MINA (HOLDINGS) LIMITED and 1 other.

How many employees does MiNA Therapeutics have?

As of Dec 31, 2024, the latest employee count at MiNA Therapeutics is 61.

Is MiNA Therapeutics a funded company?

MiNA Therapeutics is a funded company, having raised a total of $108M across 8 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 17, 2014.

How much is MiNA Therapeutics worth?

The latest valuation of MiNA Therapeutics is £***** as of Oct 20, 2021.

When was the latest funding round of MiNA Therapeutics?

MiNA Therapeutics' latest funding was a $***** Series A round on Jun 17, 2021, with participation from 1 investor.

What is the annual revenue of MiNA Therapeutics?

Annual revenue of MiNA Therapeutics is between £1M and £10M as on Dec 31, 2024

Where does MiNA Therapeutics rank among its competitors?

MiNA Therapeutics ranks 815th amongst 2962 active competitors, of which 1036 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of MiNA Therapeutics?

MiNA Therapeutics' top competitors include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

MiNA Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

MiNA Therapeutics is a series A company based in London (United Kingdom), founded in 2008 by Nagy Habib, Pal Saetrom and John Rossi. It operates as a Provider of RNA activation therapeutics. MiNA Therapeutics has raised $108M in funding from investors like Boehringer Ingelheim, aMoon and Nxera, with a current valuation of £*****. The company has 2962 active competitors, including 1036 funded and 723 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alnylam and Sana Biotechnology.

Company Details

Provider of RNA activation therapeutics. It is focused on small activating RNA therapeutics that aim to restore or boost normal gene function. The company develops a proprietary pipeline of medicines and partners with pharmaceutical companies to apply its RNA activation technology across genetic medicine and other therapeutic areas.

Website: minatx.com
Social
Email ID: *****@minatx.com, *****@minatx.com
Registered Address: Translation & Innovation Hub 80 Wood Lane London W12 0BZ United Kingdom

Key Metrics

Founded Year

2008

Location

London, United Kingdom

Stage

Series A

Total Funding

$108M in 8 rounds

Latest Funding Round

Series A, Jun 17, 2021, $*****

Post Money Valuation

£***** as on Oct 20, 2021

Investors

Boehringer Ingelheim & 18 more

Ranked

815^th among 2962 active competitors

Annual Revenue

£1M - £10M as on Dec 31, 2024

Employee Count

61 as on Dec 31, 2024

Similar Companies

Alnylam & 806 more

View MiNA Therapeutics' full profile

MiNA Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MINA (HOLDINGS) LIMITED CIN: 9293168 , United Kingdom, Active	Nov 02, 2014	£1M - £10M (As on Dec 31, 2024)	33 (As on Dec 31, 2024)
Mina Therapeutics Limited CIN: 6527890 , Germany, Active	Mar 06, 2008	£10M - £50M (As on Dec 31, 2021)	28 (As on Dec 31, 2024)

MiNA Therapeutics has raised a total funding of $108M over 8 rounds. Its first funding round was on Dec 17, 2014. Its latest funding round was a Series A round on Jun 17, 2021 for $*****. 1 investor participated in its latest round. MiNA Therapeutics has 19 institutional investors.

Here is the list of recent funding rounds of MiNA Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 17, 2021	4776236	Series A	6131440	9051755	8173684	7961678
Sep 07, 2020	5531585	Series A	2574413	4309755	2473014	7154286
May 20, 2019	3827735	Series A	4246248	5887863	4946353	2612384

Access funding benchmarks and valuations. Sign up today!

View details of MiNA Therapeutics's funding rounds and investors

The founders of MiNA Therapeutics are Nagy Habib, Pal Saetrom and John Rossi. Robert Sebastian Habib is the CEO of MiNA Therapeutics.

Here are the details of MiNA Therapeutics' key team members:

Nagy Habib: Co-Founder of MiNA Therapeutics and founder of 1 other company.
Contact Info: 1 email address
Pal Saetrom: Co-Founder of MiNA Therapeutics.
John Rossi: Co-Founder of MiNA Therapeutics.
Robert Sebastian Habib: CEO of MiNA Therapeutics. They serve on the board of 1 company.

MiNA Therapeutics' Board of Directors

MiNA Therapeutics's board has 8 active members. Robert Sebastian Habib is part of team and Norbert Bischofberger, Robert Kopple, Robert Ian Lechler, Stephanie Galantine heller, Peter James Jonathan Bains, Yael Gruenbaum cohen and Susan Elizabeth Clement davies are independent board members.

Here is the list of MiNA Therapeutics' board of directors:

Name	Type	Representing	Status	Duration
Robert Sebastian Habib	Team	-	Current	11y 8m
Norbert Bischofberger	Independent board member	-	Current	1y 3m
nqsnonq	Independent board member	-	Current	7y 3m
jdui{tu	Independent board member	-	Current	8y 1m
mp{pmdj	Independent board member	-	Current	7y 9m
kvgwtta	Independent board member	-	Current	1y 5m
jluncdf	Independent board member	-	Current	7y 8m
uxznpjs	Independent board member	-	Current	2y 5m

View details of MiNA Therapeutics's Founder profiles and Board Members

MiNA Therapeutics' employee count trend

MiNA Therapeutics has 61 employees as of Dec 24. The total employee count is 3.0% lower than what it was in Dec 23. Here is MiNA Therapeutics's employee count trend over the years:

Employee count trend for MiNA Therapeutics

Uncover MiNA Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MiNA Therapeutics include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of MiNA Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 17 others	75/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
815th	MiNA Therapeutics 2008, London (United Kingdom), Series A	Provider of RNA activation therapeutics	$108M	Lilly, aMoon & 17 others	44/100